The Journal of
Clinical Psychiatry

Suicide

Letter to the Editor December 15, 2006

Intimate Partner Violence, Suicidal Intent, and Alcoholism

József Gerevich ; Erika Bácskai

J Clin Psychiatry 2006;67(12):2030-2030

Article Abstract

Letter to the Editor

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 86 • 2025 • Number 1

Read the Current Issue

Brief Report

Sex Differences in PTSD among US Military Veterans

Commentary

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Clinical and Practical Psychopharmacology

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Commentary

Evolving Care and Research Priorities in ADHD

Original Research

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Systematic Review

Efficacy and Safety of Memantine for Children and Adults with ADHD

View current Issue

Letter to the Editor

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

July 3, 2023

Bénédicte Nobile, PharmD, PhD, and Philippe Courtet, MD, PhD, continue the discussion of potentially increased suicidal risk with daridorexant, a new hypnotic.

Bénédicte Nobile , Philippe Courtet

Letter to the Editor

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

July 3, 2023

Palagini and colleagues comment on a recent letter that suggested a role for daridorexant, a new hypnotic, in increasing suicide risk.

Laura Palagini , Pierre A. Geoffroy , Jean Arthur Micoulaud-Franchi , et al

Letter to the Editor

Possible Suicidal Risk With Daridorexant

December 7, 2022

Instructions for use of the new anti-insomnia medication daridorexant mention cautious use in patients with history of suicidal behavior. This letter explores the factors that underlie this recommendation for...

Bénédicte Nobile , Emilie Olié , Philippe Courtet

Intimate Partner Violence, Suicidal Intent, and Alcoholism

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

ELSEWHERE:

FOLLOW US:

Intimate Partner Violence, Suicidal Intent, and Alcoholism

Read the Current Issue

Sex Differences in PTSD among US Military Veterans

The Opioid Industry's Legacy: A Generation of Prescribed Suffering

Cannabis Use in Pregnancy and ASD or ADHD in Offspring

Evolving Care and Research Priorities in ADHD

Treatments and Treatment Predictors in Patients With SUDs and ADHD

Efficacy and Safety of Memantine for Children and Adults with ADHD

Related Articles

Daridorexant: Caution Is Needed About Suicidal Risk in Depressed Patients With Insomnia—Reply to Palagini et al

Aggravation of Suicide Risk With Daridorexant: Currently Not Enough Data to Show a Link

Possible Suicidal Risk With Daridorexant

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles